Phase I Clinical Trial of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2015
At a glance
- Drugs Vorinostat (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Merck & Co
- 21 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 21 Jun 2011 Status changed from active, no longer recruiting to completed reported by ClinicalTrials.gov.
- 17 Dec 2010 Official Title amended as reported by ClinicalTrials.gov (NCT00111813).